Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
Mucormycosis (zygomycosis) is an uncommon infection that afflicts severely immunocompromised patients and those with poorly controlled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the introduction and widespread use of voriconazo...
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2009-10, Vol.15, p.93-97 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 97 |
|---|---|
| container_issue | |
| container_start_page | 93 |
| container_title | Clinical microbiology and infection |
| container_volume | 15 |
| creator | Pongas, G.N. Lewis, R.E. Samonis, G. Kontoyiannis, D.P. |
| description | Mucormycosis (zygomycosis) is an uncommon infection that afflicts severely immunocompromised patients and those with poorly controlled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the introduction and widespread use of voriconazole prophylaxis in these high-risk populations. However, it is not known if this association reflects a true epidemiological link or represents a marker of changing immunosuppression occurring in parallel with the evolution of transplant practices and immunosuppression strategies. |
| doi_str_mv | 10.1111/j.1469-0691.2009.02988.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746159799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X14607370</els_id><sourcerecordid>746159799</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5098-e2db60faa468d94c3f880ad9ea6fd271c8ee65c0414cdc0e64217b1c312de3073</originalsourceid><addsrcrecordid>eNqNUcGO0zAQjRCIXRZ-AfnGKVk7cZ0YCSGoWEDqigsgbpZrT8pUSRwySWn2yJfj0AqOrC8eed6beX4vSZjgmYjnep8JqXTKlRZZzrnOeK6rKjs-SC7_Nh7GWugqLWXx7SJ5QrTnnOdFIR8nF0KXK1kqdZn8-hoGdKGzd6GB1BIFh3YEz-7mXWhnFwjpJbOMcNdhjc52I4twgh8TdA5YqBkcQnPAbsdiD-up29mG9UPov8-NPSLFZ8-wbacu0NT3AxBh6CLCuhEd0OunyaPaNgTPzvdV8uXm3ef1h3Tz6f3H9ZtN6lY8_gNyv1W8tlaqymvpirqquPUarKp9XgpXAaiV41JI5x0HJXNRboUrRO6h4GVxlbw4zY3ionoaTYvkoGlsB2EiU0olVrrUOiKrE9INgWiA2vQDtnaYjeBmCcDszeKzWXw2SwDmTwDmGKnPz0umbQv-H_HseAS8OgF-YgPzvQeb9eZ2qSL_7YkP0aoDwmDI4RKFxwHcaHzA_6v8DdKuruo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>746159799</pqid></control><display><type>article</type><title>Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Pongas, G.N. ; Lewis, R.E. ; Samonis, G. ; Kontoyiannis, D.P.</creator><creatorcontrib>Pongas, G.N. ; Lewis, R.E. ; Samonis, G. ; Kontoyiannis, D.P.</creatorcontrib><description>Mucormycosis (zygomycosis) is an uncommon infection that afflicts severely immunocompromised patients and those with poorly controlled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the introduction and widespread use of voriconazole prophylaxis in these high-risk populations. However, it is not known if this association reflects a true epidemiological link or represents a marker of changing immunosuppression occurring in parallel with the evolution of transplant practices and immunosuppression strategies.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1111/j.1469-0691.2009.02988.x</identifier><identifier>PMID: 19754766</identifier><language>eng</language><publisher>Oxford, UK: Elsevier Ltd</publisher><subject>Antifungal Agents - adverse effects ; Antifungal Agents - therapeutic use ; Chemoprevention - methods ; Drug Resistance, Fungal ; Humans ; Immunocompromised ; Immunocompromised Host ; invasive fungal infections ; Mucorales - drug effects ; mucormycosis ; Mucormycosis - etiology ; posaconazole ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Transplantation ; Triazoles - adverse effects ; Triazoles - therapeutic use ; Voriconazole ; zygomycosis</subject><ispartof>Clinical microbiology and infection, 2009-10, Vol.15, p.93-97</ispartof><rights>2009 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>2009 The Authors. Journal Compilation © 2009 European Society of Clinical Microbiology and Infectious Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5098-e2db60faa468d94c3f880ad9ea6fd271c8ee65c0414cdc0e64217b1c312de3073</citedby><cites>FETCH-LOGICAL-c5098-e2db60faa468d94c3f880ad9ea6fd271c8ee65c0414cdc0e64217b1c312de3073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1469-0691.2009.02988.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1469-0691.2009.02988.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19754766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pongas, G.N.</creatorcontrib><creatorcontrib>Lewis, R.E.</creatorcontrib><creatorcontrib>Samonis, G.</creatorcontrib><creatorcontrib>Kontoyiannis, D.P.</creatorcontrib><title>Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Mucormycosis (zygomycosis) is an uncommon infection that afflicts severely immunocompromised patients and those with poorly controlled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the introduction and widespread use of voriconazole prophylaxis in these high-risk populations. However, it is not known if this association reflects a true epidemiological link or represents a marker of changing immunosuppression occurring in parallel with the evolution of transplant practices and immunosuppression strategies.</description><subject>Antifungal Agents - adverse effects</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Chemoprevention - methods</subject><subject>Drug Resistance, Fungal</subject><subject>Humans</subject><subject>Immunocompromised</subject><subject>Immunocompromised Host</subject><subject>invasive fungal infections</subject><subject>Mucorales - drug effects</subject><subject>mucormycosis</subject><subject>Mucormycosis - etiology</subject><subject>posaconazole</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Transplantation</subject><subject>Triazoles - adverse effects</subject><subject>Triazoles - therapeutic use</subject><subject>Voriconazole</subject><subject>zygomycosis</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcGO0zAQjRCIXRZ-AfnGKVk7cZ0YCSGoWEDqigsgbpZrT8pUSRwySWn2yJfj0AqOrC8eed6beX4vSZjgmYjnep8JqXTKlRZZzrnOeK6rKjs-SC7_Nh7GWugqLWXx7SJ5QrTnnOdFIR8nF0KXK1kqdZn8-hoGdKGzd6GB1BIFh3YEz-7mXWhnFwjpJbOMcNdhjc52I4twgh8TdA5YqBkcQnPAbsdiD-up29mG9UPov8-NPSLFZ8-wbacu0NT3AxBh6CLCuhEd0OunyaPaNgTPzvdV8uXm3ef1h3Tz6f3H9ZtN6lY8_gNyv1W8tlaqymvpirqquPUarKp9XgpXAaiV41JI5x0HJXNRboUrRO6h4GVxlbw4zY3ionoaTYvkoGlsB2EiU0olVrrUOiKrE9INgWiA2vQDtnaYjeBmCcDszeKzWXw2SwDmTwDmGKnPz0umbQv-H_HseAS8OgF-YgPzvQeb9eZ2qSL_7YkP0aoDwmDI4RKFxwHcaHzA_6v8DdKuruo</recordid><startdate>200910</startdate><enddate>200910</enddate><creator>Pongas, G.N.</creator><creator>Lewis, R.E.</creator><creator>Samonis, G.</creator><creator>Kontoyiannis, D.P.</creator><general>Elsevier Ltd</general><general>Blackwell Publishing Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>M7N</scope></search><sort><creationdate>200910</creationdate><title>Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?</title><author>Pongas, G.N. ; Lewis, R.E. ; Samonis, G. ; Kontoyiannis, D.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5098-e2db60faa468d94c3f880ad9ea6fd271c8ee65c0414cdc0e64217b1c312de3073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antifungal Agents - adverse effects</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Chemoprevention - methods</topic><topic>Drug Resistance, Fungal</topic><topic>Humans</topic><topic>Immunocompromised</topic><topic>Immunocompromised Host</topic><topic>invasive fungal infections</topic><topic>Mucorales - drug effects</topic><topic>mucormycosis</topic><topic>Mucormycosis - etiology</topic><topic>posaconazole</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Transplantation</topic><topic>Triazoles - adverse effects</topic><topic>Triazoles - therapeutic use</topic><topic>Voriconazole</topic><topic>zygomycosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pongas, G.N.</creatorcontrib><creatorcontrib>Lewis, R.E.</creatorcontrib><creatorcontrib>Samonis, G.</creatorcontrib><creatorcontrib>Kontoyiannis, D.P.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pongas, G.N.</au><au>Lewis, R.E.</au><au>Samonis, G.</au><au>Kontoyiannis, D.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2009-10</date><risdate>2009</risdate><volume>15</volume><spage>93</spage><epage>97</epage><pages>93-97</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Mucormycosis (zygomycosis) is an uncommon infection that afflicts severely immunocompromised patients and those with poorly controlled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the introduction and widespread use of voriconazole prophylaxis in these high-risk populations. However, it is not known if this association reflects a true epidemiological link or represents a marker of changing immunosuppression occurring in parallel with the evolution of transplant practices and immunosuppression strategies.</abstract><cop>Oxford, UK</cop><pub>Elsevier Ltd</pub><pmid>19754766</pmid><doi>10.1111/j.1469-0691.2009.02988.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2009-10, Vol.15, p.93-97 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746159799 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Chemoprevention - methods Drug Resistance, Fungal Humans Immunocompromised Immunocompromised Host invasive fungal infections Mucorales - drug effects mucormycosis Mucormycosis - etiology posaconazole Pyrimidines - adverse effects Pyrimidines - therapeutic use Transplantation Triazoles - adverse effects Triazoles - therapeutic use Voriconazole zygomycosis |
| title | Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A01%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Voriconazole-associated%20zygomycosis:%20a%20significant%20consequence%20of%20evolving%20antifungal%20prophylaxis%20and%20immunosuppression%20practices?&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Pongas,%20G.N.&rft.date=2009-10&rft.volume=15&rft.spage=93&rft.epage=97&rft.pages=93-97&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1111/j.1469-0691.2009.02988.x&rft_dat=%3Cproquest_cross%3E746159799%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=746159799&rft_id=info:pmid/19754766&rft_els_id=S1198743X14607370&rfr_iscdi=true |